Autor: |
Shahdi K. Malakooti, Hinnah Siddiqui, Brigid Wilson, Taissa Bej, Megan O’Mara, Alexandra Desotelle, Alyssa Lange, Carey L. Shive, Nora G. Singer, Grace A. McComsey, Lenche Kostadinova, Maya Mattar, David A. Zidar, Donald D. Anthony |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Nutrients, Vol 16, Iss 3, p 401 (2024) |
Druh dokumentu: |
article |
ISSN: |
2072-6643 |
DOI: |
10.3390/nu16030401 |
Popis: |
(1) Vitamin D deficiency is associated with mortality in the general population and has been observed in one rheumatoid arthritis (RA) cohort. Here, we investigate the relationship between 25-hydroxyvitamin D (25(OH)D) levels before methotrexate (MTX) therapy initiation in patients with RA and the subsequent all-cause mortality in a national Veterans Affairs (VA) cohort. (2) This is a retrospective study on RA patients time-oriented around the initial MTX prescription and 25(OH)D levels before starting MTX. We examined survival in patients with 25(OH)D levels > 50 nmol/L and ≤50 nmol/L using the Cox Proportional Hazard Model and fully adjusted for risk factors. (3) In total, 15,109 RA patients were included in the nationwide cohort. RA patients with 25(OH)D levels > 50 nmol/L before starting MTX had a 28% reduced risk of mortality when compared to those with levels ≤ 50 nmol/L (HR: 0.72, CI: 0.64–0.80, p < 0.001) after adjusting for traditional risk factors. (4) In this national RA cohort receiving standard-of-care MTX, patients with 25(OH)D levels > 50 nmol/L have a lower subsequent mortality when compared to those with 25(OH)D levels ≤ 50 nmol/L. It remains to be determined whether increasing Vitamin D levels in RA patients initially found to be Vitamin D deficient impacts their all-cause mortality. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|